

Association between comorbidities and death from COVID-19 in different age groups

Pedro Emanuel Fleitas^{a,b*}, María Cristina Almazán^{a,b}, Sabrina Daniela Cortez^b, Jorge Augusto Paz^c, Rubén Oscar Cimino^{a,b}, Alejandro Javier Krolewiecki^a

- a. Instituto de Investigaciones de Enfermedades Tropicales (IIET-CONICET), Universidad Nacional de Salta. Alvarado 751. San Ramón de la Nueva Orán, Salta, Argentina. ZC: 4530.
- b. Cátedra de Química Biológica, Facultad de Ciencias Naturales, Universidad Nacional de Salta. Avenida Bolivia 5150. Salta, Argentina. ZC: 4400.
- c. Instituto de Estudios Laborales y del Desarrollo Económico (IELDE), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad Nacional de Salta. Avenida Bolivia 5150. Salta, Argentina. ZC: 4400.

* **Corresponding autor:** PhD. Pedro E. Fleitas

Mail: pedro.fleittas@gmail.com

Tel: +5493424408448

Work address: Instituto de Investigaciones de Enfermedades Tropicales (IIET). Alvarado 751, San Ramón de la Nueva Orán, Salta, Argentina. Zip Code: 4530.

20 **Abstract**

21 **Background:** This new COVID-19 pandemic challenges health systems around the world;
22 therefore, it is extremely important to determine which patients with COVID-19 can evolve to
23 more severe outcomes. Accordingly, we decided to assess the role that comorbidities play in
24 death from COVID-19.

25 **Methods:** Two age groups (<60 and ≥ 60 years) were defined for analysis. Decision trees were
26 made to identify which comorbidities had the highest fatality rate (FR). Multiple logistic
27 regressions were performed to measure the association between comorbidities and death.

28 **Results:** A significant difference was found between the FR of <60 group and ≥ 60 group. The
29 most frequent comorbidity were cardiac diseases and diabetes. The combination of comorbidities
30 with the highest FR was diabetes with kidney disease. Combinations of more than two
31 comorbidities presented higher FR. The comorbidities had higher Odd ratios in the younger
32 group than in the older group.

33 **Conclusions:** Comorbidities seem to play a greater role in death from COVID-19 in the younger
34 group, while in the > 60 group; age seems to be the most important factor. We assigned a score to
35 the comorbidities and their combinations for both age groups to help the health personnel make
36 decisions.

37 **Keywords**

38 COVID-19; Comorbidities; Fatality rate; Score

39

40 **Introduction**

41 From the first case of COVID-19 that was reported in the city of Wuhan, China in December
42 2019 until the beginning of November 2020, 46 million infected people have been reported
43 worldwide.¹ Of these 46 million, 2.6% have died.¹ This new pandemic challenges health systems
44 around the world and carries important ethical questions, especially under the need of rationing
45 health care in the context of scarce resources and crisis capacity.² For this reason, it is extremely
46 important to determine which patients with COVID-19 can evolve to more severe outcomes,
47 including death. Age, male gender, and ethnicity have all been reported to be associated with
48 severe COVID-19 outcomes.^{3,4} Also, comorbidities such as diabetes, kidney, respiratory, and
49 cardiovascular diseases have been reported as risk factors for severe outcomes by COVID-19.^{3,5}
50 Based on this, we decided to assess the role that comorbidities play in death from COVID-19 in a
51 large database from Brazil that includes recovered and deceased patients, to provide valuable
52 information for designing strategies for case management.

53 **Material and methods**

54 **Data source**

55 The data file was downloaded from the website of the Brazilian Ministry of Health on August 1,
56 2020.⁶ The data comes from the e-SUS NOTIFICA system, which was developed to register
57 suspected cases of COVID-19 in Brazil, and contains patient information such as place of
58 residence, clinical, demographic, and epidemiological characteristics. An *ad-hoc* database was
59 built for this project with all laboratory confirmed positive cases (RT-PCR or serology) or
60 clinical-epidemiological survey containing information on date of onset of symptoms, date of the

61 diagnostic test, age, sex, and disease evolution. Patients with missing data were excluded from
62 the database. We did not impose any further exclusion criteria to limit selection bias.

63 **Study design**

64 Two age-group were defined for the analysis with those <60 or ≥ 60 years-old. Decision trees
65 were built to order the comorbidities according to their frequency and the proportion of deaths
66 from COVID-19 reported. Then, the correlation of the absence/presence of the following
67 comorbidities: diabetes, immunosuppression, kidney, respiratory, and cardiovascular disease with
68 death from COVID-19 was analyzed. For this, a multiple logistic regression was performed to
69 identify which variables were associated with death from COVID-19. Also, the probability
70 obtained from logistic regressions (probability of dying when infected by COVID-19 if the
71 comorbidities were present) was used to calculate the area under the receiver-operator
72 characteristic curve (AUC). The AUC was used as a measure of the ability of the comorbidities
73 model to predict death from COVID-19. Finally, the values of probability obtained from logistic
74 regressions were used to assign a score to the comorbidities and the combinations of them. All
75 statistical analyses were carried with RStudio version 1.3.1093 (RStudio: Integrated
76 Development for R. RStudio, PBC, Boston, MA). Analyses with p-values <0.05 for a level of
77 significance of 95% were considered statistically significant. Figures were done with GraphPad
78 Prime 9 Trial version (GraphPad Software Inc., San Diego, CA).

79 **Results**

80 **Data description**

81 The whole database includes over 8 million cases recorded in the 27 states of Brazil from January
82 1 to August 1 2020, 549733 were included in the analysis (Fig. 1). A summary of the

83 comorbidities registered in all the patients can be observed in Table S1 of supplementary
84 material. In our database, median age was 38 years old (IQR: 30-51); 46% were males and 54%
85 females. It was found that 2.1% of patients died while 97.9% were recovered. A statistically
86 significant difference was found between the fatality rate of <60 group (0.7%, n= 457557) and \geq
87 60 group (11.3% n= 74176) ($p<0.01$) (Fig. 2). Also, the median time between the onset of
88 symptoms and death was 20 days (IQR: 12-33), and no differences were found between age
89 groups.

90 Five comorbidities were recorded in the data file: cardiovascular disease, immunosuppression,
91 kidney disease, respiratory disease, and diabetes. Among 87.6% of the cases, no comorbidities
92 were registered; meanwhile, the most frequent comorbidity registered in the database was
93 cardiovascular disease (7.2% (39542/549733)), followed by diabetes (4.3% (23966/549733)),
94 respiratory disease (2.0% (11035/549733)), immunosuppression (0.9% (4934/549733)) and
95 kidney disease (0.5% (2684/549733)). In addition, It was observed that in the <60 group, cardiac
96 disease (Frequency= 4.3%) and diabetes (Frequency= 2.6%) presented a fatality rate of 1.6% and
97 0.5% (Fig. 3a). In addition, the highest fatality rate (19%) was found in individuals with diabetes
98 and kidney disease (Fig. 3a). In the ≥ 60 group the most frequent comorbidities were also diabetes
99 (Frequency =15%, fatality rate =19%) and cardiovascular disease, without diabetes, (Frequency
100 =12.4%, fatality rate =13%). At the same time, the combination of comorbidities with the highest
101 fatality rate was diabetes with kidney disease (fatality rate= 35%) and diabetes with kidney and
102 respiratory diseases (fatality rate= 47%) (Fig. 3b).

103

104

105 **Figure 1:** Flowchart of data used in this study. *According to Guidelines for Case Notification of
106 Influenza Syndrome suspected of COVID-19.⁷

107

108 **Figure 2:** Frequency of recovery and death from COVID-19, according to the patient's age.

109

110 **Figure 3:** Tree diagrams representing the frequency of the comorbidities and the fatality rate. **a.**
111 <60 group (n=457557). **b.** ≥ 60 group (n=74176). In each node, its number is represented in the
112 top, and inside the fatality rate (MR) and the percentage frequency (F). DBT= Diabetes, IS =
113 immunosuppression, KD = kidney disease, RD = respiratory disease, CD= Cardiovascular
114 disease, P= comorbidity present and A= comorbidity absent.

115 **Correlation among comorbidities and death from COVID-19**

116 For the <60 group and ≥ 60 groups, the values of AUC=0.66 and AUC=0.61 were obtained,
117 respectively. As Fig. 4 shows, the comorbidities had higher ORs in the <60 group than in the ≥
118 60 group. In this first group, diabetes, kidney disease, and immunosuppression had the highest
119 ORs; whereas in the ≥60 group, the comorbidities with the highest ORs were kidney and
120 respiratory diseases (Fig. 4).

121 The logistic regression allowed us to assign a score to the comorbidities and their combinations,
122 from one (lower probability of a severe outcome) to eight (high probability of a severe outcome)
123 for both age groups. These scores were ordered into three categories of low, medium, and high
124 risk, based on the incidence of death from COVID-19. It can be observed that the highest score is

125 found with the combination of diabetes and kidney disease or the combination of 3 or more
 126 comorbidities.

127 **Figure 4:** Odds ratios for comorbidities in the <60 group and ≥60 age group.

128

129 **Table 1:** Score assigned to the different comorbidities based on the probability of death when
 130 infected by COVID-19 (multivariate logistic regression) and the fatality rate.

<60 group			
Score range		Comorbidities	Assigned score
Low Score	Probability <0.02 Fatality rate =0.5 n=458076	Cardiovascular disease	1
		Respiratory disease	1
Medium Score	Probability =0.02-0.04 Fatality rate =4.0 n=12352	Cardiovascular disease + Respiratory disease	2
		Immunosuppression	2.5
		Kidney disease	3
		Diabetes	3.5
High Score	Probability ≥0.05 Fatality rate =7.0 n=5129	Immunosuppression + Respiratory disease	4
		Kidney disease + Respiratory disease	5
		Diabetes + Respiratory disease	5.5
		Immunosuppression + Cardiovascular disease	6

		Cardiovascular disease + Renal disease	6.5
		Diabetes + cardiovascular disease	7
		Immunosuppression + Kidney disease	7.5
		Diabetes + Kidney disease or ≥ 3 comorbidities	8

131

≥ 60 group			
Score range		Comorbidities	Assigned score
Low Score	Probability <0.17 Fatality rate =9.9 n=65466	Cardiovascular disease	1
		Immunosuppression	1
		Diabetes	1
Medium Score	Probability 0.17-0.29 Fatality rate=20.7 n=7801	Respiratory disease	2
		Immunosuppression + Cardiovascular disease	2.5
		Kidney disease	3
		Cardiovascular disease + diabetes	3.5
		Diabetes + Immunosuppression	4
		Cardiovascular disease + Respiratory disease	4.5
		Immunosuppression + Respiratory disease	5
		Cardiovascular disease + Kidney disease	5.5
		Diabetes + Respiratory disease	6
Immunosuppression + Kidney	6.5		

		disease	
High Score	Probability ≥ 0.29 Fatality rate = 30.1 n=909	Renal disease + Respiratory disease	7
		Diabetes + Kidney disease or ≥ 3 comorbidities	8

132

133

134 **Discussion**

135 Since the beginning of the COVID-19 pandemic in December 2019, the reported case fatality rate
136 has varied. Early estimates from small cohorts of hospitalized patients indicated a fatality rate of
137 15%; later and with more data, the percentage of deaths fell from 11% to 4.3% and finally to
138 3.4%.⁸ In addition, 81% of patients with COVID-19 have a mild illness and never require
139 hospitalization.⁹ Therefore, for a better understanding of the causes that lead to severe results of
140 COVID-19, in this retrospective cohort study, we analyzed risk factors for death in individuals
141 with COVID-19 in a large database from Brazil with a fatality rate of 2.1%.

142 Older age has been reported by several authors as an important factor associated with the severity
143 of the disease or fatality in patients with COVID-19.^{4,5,10} In accordance with this, we found a
144 higher fatality rate in patients older than 60 years of age.

145 It is important to highlight the relevance of age-stratified analyses when examining the
146 association between comorbidities and fatality with COVID-19.⁵ In our study, the odd ratio (OR)
147 values for comorbidities varied depending on age group. In the <60 group, both higher ORs and a
148 higher AUC value were observed compared to those obtained for the ≥ 60 group. This suggests

149 that the comorbidities considered are able to better explain the fatality from COVID-19 in the
150 <60 group than in the ≥ 60 group. Therefore, the comorbidities seem to have an important impact
151 on death in the <60 group, while in the ≥ 60 group the comorbidities might play a minor role in
152 death from COVID-19. This suggests that the main risk factor in the older group is age itself,
153 which is consistent with previous findings for Brazilians patients.³

154 Diabetes was the most frequent comorbidity and had the highest OR value in the <60. Patients
155 who presented diabetes as comorbidity, reached a fatality rate of 0.5% and 19% in the <60 group
156 and ≥ 60 group, respectively (Fig. 2). Worth mentioning, Brazil is one of the countries with more
157 diabetes cases in the world, being the estimated prevalence of 11.9 % (95 % CI 7.7–17.8).¹¹ The
158 evolution of COVID-19 has shown to be more severe in patients with diabetes and metabolic
159 dysfunction.¹² Recent data suggests that COVID-19 could precipitate acute metabolic
160 complications of diabetes, such as diabetic ketoacidosis and hyperglycemia. The potential
161 mechanisms that may increase susceptibility to severe COVID-19 in patients with diabetes
162 include: 1) higher affinity cell binding and effective entry of the virus, 2) decreased viral
163 clearance, 3) decreased T cell function, 4) increased susceptibility to hyperinflammation and
164 cytokine storm syndrome, and 5) presence of cardiovascular diseases.¹³ This becomes more
165 relevant when considering that the most frequent combination of comorbidities included diabetes
166 and cardiovascular disease, with a fatality rate of 6% and 20% in the <60 group and ≥ 60 group,
167 respectively.

168 Another important risk factor is kidney disease. In the ≥ 60 group, this comorbidity together with
169 respiratory disease presented the highest ORs. Moreover, the combination of diabetes with
170 kidney disease caused the highest fatality rates. Since diabetes is the main cause of chronic
171 kidney disease,¹⁴ patients with these two comorbidities can represent diabetic patients in a more

172 severe stage of the disease or without adequate medical care. Interestingly, the human kidney has
173 been reported to be a target for SARS-CoV-2¹⁵; however, it remains controversial whether
174 SARS-CoV-2 causes acute kidney injury.¹⁶

175 There is a wide spectrum of immunosuppressed patients, including patients with cancer, solid
176 organ transplant recipients, those taking antirheumatic drugs, primary immunodeficiency, and
177 HIV infection. We found that in both age groups, immunosuppression was a risk factor
178 associated with death from COVID-19. However, this should be interpreted with caution since
179 the database did not allow to determine precisely the underlying cause of the immunosuppression
180 and because there is controversy about the role immunosuppression in COVID-19. Previous
181 research indicates that patients with cancer and solid organ transplant recipients may have a
182 higher risk of developing more severe COVID-19.^{17,18} Nonetheless, immunosuppressed adults
183 with no further comorbidities might not be likely to have a severe clinical outcome.¹⁸ This
184 contradiction may be because the host's immune response is an important factor contributing to
185 the severity of COVID-19, through a dysregulation of innate immunity or an excessive
186 inflammatory response.¹⁹ Thus, immunosuppression, as a sole comorbidity, probably does not
187 determine a severe outcome.

188 As has been shown in this study, there are comorbidities that increase the probability of severe
189 COVID-19. Therefore, they should be considered in case management. Concerning this, we
190 assigned a score to each comorbidity to provide a possible order of priority. Based on the analysis
191 of this large database, there are small subgroups of cases that carry an exceedingly high risk of
192 death due to COVID-19.

193 It is important to understand the limitations of this study when interpreting these results. First,
194 possible selection biases cannot be ruled out due to the reduction of the data file. Second, the data
195 come from all the states of Brazil, but might not be representative of the entire population, and
196 the generalizability of the results beyond this cohort is unclear. However, it is worth noting the
197 high number of cases analyzed and that the proportion of the comorbidities in the database
198 (n=549733) is similar to in the original data file (n=8056794).

199 In conclusion, we demonstrate that diabetes, kidney disease, respiratory disease, cardiovascular
200 disease, and immunosuppression are risk factors related to death from COVID-19, where age
201 seems to be a determining factor. The combination of comorbidities increases the risk, which
202 must be considered and analyzed for clinical decisions.

203 **Competing interests:** The authors declare that they have no competing interests.

204 **Funding:** This article did not have any kind of funding.

205 **Ethics approval:** The material used was freely available on the website of the Brazilian Ministry
206 of Public Health, so it was not necessary to have ethical approval.


207 **Supplementary materials:** Supplementary material associated with this article can be found in
208 the online version.


209 **References**


- 210 1. Hopkins C for SS and E (CSSE) J. COVID-19 Map - Johns Hopkins Coronavirus
211 Resource Center. Accessed May 5, 2020. <https://coronavirus.jhu.edu/map.html>
- 212 2. Curtis JR, Kross E, Stapleton R. The Importance of Addressing Advance Care Planning
213 and Decisions About Do-Not-Resuscitate Orders During Novel Coronavirus 2019
214 (COVID-19). *JAMA*. 2020;346(323):1771-1772. doi:10.1056/nejmsa012528.
- 215 3. Baqui P, Bica I, Marra V, Ercole A, van der Schaar M. Ethnic and regional variations in
216 hospital mortality from COVID-19 in Brazil: a cross-sectional observational study. *Lancet*


- 217 *Glob Heal.* 2020;8(8):e1018-e1026. doi:10.1016/S2214-109X(20)30285-0.
- 218 4. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei
219 Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for
220 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort
221 study. *Lancet.* 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3.
- 222 5. Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities
223 associated with mortality in 31,461 adults with COVID-19 in the United States: A
224 federated electronic medical record analysis. *PLoS Med.* 2020;17(9):1-11.
225 doi:10.1371/JOURNAL.PMED.1003321.
- 226 6. Notificações de Síndrome Gripal - Conjuntos de dados - Open Data. Accessed August 1,
227 2020. <https://opendatasus.saude.gov.br/dataset/casos-nacionais>
- 228 7. MINISTÉRIO DA SAÚDE Guia de ViGilância Epidemiológica EmerGência de Saúde
229 Pública de Importância Nacional Pela Doença Pelo CoronaVírus 2019. Accessed
230 November 6, 2020. <http://www.saude.gov.br/svs>
- 231 8. Rajgor DD, Lee MH, Archuleta S, Bagdasarian N, Quek SC. The many estimates of the
232 COVID-19 case fatality rate. *Lancet Infect Dis.* 2020;20(7):776-777. doi:10.1016/S1473-
233 3099(20)30244-9.
- 234 9. Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. *Lancet.*
235 2020;395(10229):1014-1015. doi:10.1016/S0140-6736(20)30633-4.
- 236 10. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, Cuomo-Dannenburg G,
237 Thompson H, Walker PGT, Fu H, Dighe A, Griffin JT, Baguelin M, Bhatia S, Boonyasiri
238 A, Cori A, Cucunubá Z, FitzJohn R, Gaythorpe K, Green W, Hamlet A, Hinsley W,
239 Laydon D, Nedjati-Gilani G, Riley S, van Elsland S, Volz E, Wang H, Wang Y, Xi X,
240 Donnelly CA, Ghani AC, Ferguson NM. Estimates of the severity of coronavirus disease
241 2019: a model-based analysis. *Lancet Infect Dis.* 2020;20(6):669-677. doi:10.1016/S1473-
242 3099(20)30243-7.
- 243 11. Telo GH, Cureau FV, De Souza MS, Andrade TS, Copês F, Schaan BD. Prevalence of
244 diabetes in Brazil over time: A systematic review with meta-analysis. *Diabetol Metab*
245 *Syndr.* 2016;8(1):1-13. doi:10.1186/s13098-016-0181-1.
- 246 12. The Lancet Diabetes & Endocrinology. COVID-19 and diabetes: a co-conspiracy? *Lancet*
247 *Diabetes Endocrinol.* 2020;8(October):801.
- 248 13. Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. *Am J*
249 *Physiol - Endocrinol Metab.* 2020;318(5):E736-E741. doi:10.1152/ajpendo.00124.2020.
- 250 14. Pyram R, Kansara A, Banerji MA, Loney-Hutchinson L. Chronic kidney disease and
251 diabetes. *Maturitas.* 2012;71(2):94-103. doi:10.1016/j.maturitas.2011.11.009.
- 252 15. Diao B, Wang C, Wang R, Feng Z, Tan Y, Wang H, Wang C, Liu L, Liu Y, Liu Y, Wang
253 G, Yuan Z, Ren L, Wu Y, Chen Y. Human Kidney is a Target for Novel Severe Acute
254 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. *Publ Online.* 2020.
- 255 16. Zhou H, Zhang Z, Fan H, Li J, Li M, Dong Y, Guo W, Lin L, Kang Z, Yu T, Tian C, Gui

- 256 Y, Qin R, Wang H, Luo S, Hu D. Urinalysis, but not blood biochemistry, detects the early
257 renal-impairment in patients with COVID-19. *SSRN Electron J.* 2020.
258 doi:10.1101/2020.04.03.20051722.
- 259 17. Fung M, Babik JM. COVID-19 in Immunocompromised Hosts: What We Know So Far.
260 *Clin Infect Dis.* 2020. doi:10.1093/cid/ciaa863.
- 261 18. Minotti C, Tirelli F, Barbieri E, Giaquinto C, Donà D. How is immunosuppressive status
262 affecting children and adults in SARS-CoV-2 infection? A systematic review. *J Infect.*
263 2020;81(1):e61-e66. doi:10.1016/j.jinf.2020.04.026.
- 264 19. Abdulmir AS, Hafidh RR. The possible immunological pathways for the variable
265 immunopathogenesis of COVID—19 infections among healthy adults, elderly and
266 children. *Electron J Gen Med.* 2020;17(4):1-4. doi:10.29333/ejgm/7850.





a.

b.

- ≥ 60 years old
- > 60 years old

